The National Cancer Center Hospital in Tokyo upgrades its MRIdian® Linac for MRI-guided radiation therapy and has treated its first patients

The largest cancer center in Japan Improves its real-time soft tissue tracking and adaptive tabletop delivery with the MRIdian system

CLEVELAND, August 11, 2022 /PRNewswire/ — ViewRay, Inc. (NASDAQ: VRAY) today announced that the National Cancer Center Hospital (NCCH) of Japan upgraded its Cobalt MRIdian® MRI-guided radiation therapy system to the MRIdian Linac system and treated its first patients. The MRIdian system will enable the National Cancer Center Hospital to offer advanced MRI-guided radiation therapy technology to cancer patients seeking personalized treatment for pancreatic, prostate, lung, liver, breast and oligometastatic cancers.

CNC purchased its first MRIdian system in September 2016 after Shonin’s approval of Japan’s Ministry of Health, Labor and Welfare (MHLW) cobalt system the previous month. On the July 25, 2022, NCCH treated its first patient with a full table-top adaptive workflow on MRIdian’s enhanced version of Linac. MRIdian Linac features a linear accelerator and enables daily table-top adaptive radiation therapy and real-time monitoring to dynamically adjust radiation beam delivery for subtle anatomical changes that may occur, both during the delivery of the treatment and throughout treatment. Combined, these capabilities help clinicians improve targeting accuracy and therefore deliver higher radiation doses.

“Over the past 6 years we have seen firsthand the benefits of real-time MRI guidance and tabletop adaptive treatment delivery and its value in improving outcomes for cancer patients, we are therefore looking forward to integrating the MRIdian Linac system to further enhance our MRI-guided radiotherapy offerings,” said Dr. Kazuaki Shimada, director of the National Cancer Center Hospital. “MRIdian’s triggering technology is second to none and allows us to be aggressive in our delivery of stereotactic body radiation therapy, as we can be confident that the dose is precisely hitting the target without collateral damage to surrounding healthy tissue, can deliver the best care medical services to society,” said Dr. Hiroshi IgakiHead, Department of Radiation Oncology.

Japan is the world’s third-largest radiation oncology market, and the National Cancer Center Hospital is one of the from Japan leading national cancer treatment centers providing patient care for over 60 years. The National Cancer Center is at the forefront of cancer treatment research and plays a central role in training doctors, nurses, and other healthcare professionals to specialize in cancer medicine.

The MRIdian system provides oncologists with exceptional anatomical visualization through diagnostic-quality MRI images and the ability to tailor a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to set narrow treatment margins to avoid unnecessary radiation exposure to vulnerable organs at risk and healthy tissues and allows the delivery of ablative radiation doses in five treatment sessions or less, without relying on implanted markers. By providing continuous real-time tracking of the target and organs at risk, MRIdian enables automatic radiation beam triggering if the target moves outside of user-defined margins. This allows the prescribed dose to be delivered to the target, while sparing surrounding healthy tissue and critical structures, minimizing the toxicities typically associated with conventional radiation therapy.

Nearly 25,000 patients have been treated with IRMdian. Currently, 53 MRI systems are installed in hospitals around the world where they are used to treat a wide variety of solid tumors and are the subject of many ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. For a list of treatment centers, please visit:

Nothing in this document is intended to provide specific medical advice or to replace written law or regulation.

Security statement
The MRIdian Linac system is not suitable for all patients, including those who are not candidates for magnetic resonance imaging. Radiation therapies can cause side effects that can vary depending on the part of the body being treated. The most common are usually temporary and may include, but are not limited to, irritation of the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be serious. Treatment sessions can vary in complexity and duration. Radiation therapy is not appropriate for all cancers. You should discuss the potential for side effects and their severity and the benefits of radiation therapy and magnetic resonance imaging with your doctor to make sure radiation therapy is right for you.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MRI-guided radiation therapy system. MRIdian is built on a proprietary high-definition MR imaging system designed from the ground up to meet the unique challenges and clinical workflow of advanced radiation oncology. Unlike MRI systems used in diagnostic radiology, MRIdian’s high-definition MRI has been specifically designed to address specific challenges including beam distortion, skin toxicity, and other issues that can arise when high magnetic fields interact with beams of radiation. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-looking statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among other things, ViewRay’s financial forecast for the full year 2022, expected future orders, expected future operational and financial performance, treatment outcomes, therapy uptake, innovation and performance of MRIdian systems. Actual results could differ from those projected in the forward-looking statements due to many factors. These factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay’s products, ability to convert backlog into revenue, timing of delivery of ViewRay’s products, timing, and the severity of the COVID-19 pandemic, including its impacts on our on-demand business, global operations and supply chains, results and other uncertainties associated with clinical trials, the ability to raise additional necessary funds to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with the development of new products or technologies, competition in the industry in which ViewRay operates and general market conditions. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business generally, see ViewRay’s current and future reports filed with of the Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended December 31, 2021 and its quarterly reports on Form 10-Q, updated periodically along with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay undertakes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law.

SOURCE ViewRay, Inc.

Comments are closed.